Daré Bioscience, Inc.
DAREHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeDaré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. With a market capitalization of $12.7M, it sits in micro-cap territory. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Market Cap
$12.7M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-1.56
EPS (TTM)
$-0.71
EPS (Fwd)
$-0.41
ROE
—
ROA
-39.3%
Cash
$12.6M
Total Debt
$6.8M
Free CF
-$6.9M
52W Change
-69.4%
Annual Financials
Cash vs Debt
Where DARE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DARE finished 55.62% below its 150-day moving average ($1.60) and 56.71% below its 200-day moving average ($1.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DARE overbought or oversold?
At the October 20, 2026 close, DARE's RSI(14) was 23.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $12.6M in cash comfortably exceeding the $6.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$6.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $10.0M (2022) to $1.0M (2025), a 90% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DARE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.